DavidHuangMD

PubMed

• 5 citations
  Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-XL and BCL-2.
  M.J. Roy, Amelia Vom, Toru Okamoto, Brian J. Smith, Richard W Birkinshaw, Hong Yang, Houda Abdo, Christine A White, David J. Segal, David C.S. Huang, Jonathan B. Baell...> ;Journal of Medicinal Chemistry. 2021 Apr 27
• 49 citations
  PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling.
  Bing Yao, Tao Gui, Xiangwei Zeng, Yexuan Deng, Zhi Wang, Ying Wang, Dongjun Yang, Qixiang Li, Peipei Xu, Ruifeng Hu, Xinyu Li, Bing Chen, Jin Wang, Ke Zen, Haitao Li, ...> ;Genome Medicine. 2021 Apr 14
• 62 citations
  Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
  Rachel Thijssen, Sarah T. Diepstraten, Donia M Moujalled, Edward Chew, Christoffer Flensburg, Melissa X Shi, Michael A. Dengler, Veronique Litalien, Sarah MacRaild, Ma...> ;Blood. 2021 May 20
• 10 citations
  BH3 Mimetics for the Treatment of B-Cell Malignancies-Insights and Lessons from the Clinic.
  Victor S Lin, Zhuo-Fan Xu, David C.S. Huang, Rachel Thijssen> ;Cancers. 2020 Nov 12
• 16 citations
  The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival.
  Pasquale L. Fedele, Yang Liao, Jia-Nan Gong, Yuan Yao, Mark F. van Delft, Michael S.Y. Low, Lin Tai, Marco J Herold, Jacob T. Jackson, Charis E Teh, Tania Tan, Lorrain...> ;Leukemia. 2020 Nov 4
• 20 citations
  Potent Inhibition of Necroptosis by Simultaneously Targeting Multiple Effectors of the Pathway.
  Catia L Pierotti, Maria C. Tanzer, Annette V. Jacobsen, Joanne M Hildebrand, Jean-Marc Garnier, Pooja Sharma, Isabelle S Lucet, Angus D. Cowan, Wilhelmus J A Kersten, ...> ;ACS Chemical Biology. 2020 Sep 9
• 10 citations
  Defining the susceptibility of colorectal cancers to BH3-mimetic compounds.
  Ming-Jie Luo, Michelle Palmieri, Chris D. Riffkin, Anuratha Sakthianandeswaren, Tirta Mario Djajawi, Yumiko Hirokawa, Victoria G. Shuttleworth, David J. Segal, Christi...> ;Cell Death & Disease. 2020 Sep 10
• 21 citations
  Cotargeting BCL-2 and MCL-1 in high-risk B-ALL
  Donia M Moujalled, Diane T Hanna, Soroor Hediyeh-Zadeh, Giovanna Pomilio, Lauren M Brown, Veronique Litalien, Ray Bartolo, Shaun Fleming, Maïa Chanrion, Sébastien Banq...> ;Blood Advances. 2020 Jun 23
• 5 citations
  Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells.
  Rachel Thijssen, Silvia Alvarez-Diaz, Clea Grace, Ming-Yuan Gao, David J. Segal, Zhen Xu, Andreas Strasser, David C.S. Huang> ;Cell Death and Differentiation. 2020 Jun 18
• 32 citations
  EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins.
  Leah Fitzsimmons, Rachel Cartlidge, Catherine Chang, Nenad Sejic, Laura C. A. Galbraith, Chathura D. Suraweera, D. Croom-Carter, Grant Dewson, Rosemary J. Tierney, And...> ;Cell Death and Differentiation. 2020 May 1
• 354 citations
  Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
  Courtney D. DiNardo, Ing Soo Tiong, A. Quaglieri, Sarah MacRaild, Sanam Loghavi, Fiona C. Brown, Rachel Thijssen, Giovanna Pomilio, Adam Ivey, Jessica M. Salmon, Chris...> ;Blood. 2020 Mar 12
• 90 citations
  Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
  Piers Blombery, Ella R. Thompson, Tamia Nguyen, Richard W Birkinshaw, Jia-Nan Gong, Xiangting Chen, Michelle McBean, Rachel Thijssen, Thomas C. Conway, Mary Ann Anders...> ;Blood. 2020 Mar 5
• 25 citations
  MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1:NOXA complex.
  Tirta Mario Djajawi, Lei Liu, Jia-Nan Gong, Allan Shuai Huang, Ming-Jie Luo, Zhen Xu, Toru Okamoto, Melissa J. Call, David C. S. Huang, Mark F. van Delft> ;Cell Death and Differentiation. 2020 Feb 24
• 21 citations
  Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells
  Charis E Teh, Jia-Nan Gong, David J. Segal, Tania Tan, Cassandra J. Vandenberg, Pasquale L. Fedele, Michael Low, George Grigoriadis, Simon J. Harrison, Andreas Strasse...> ;Cell Death and Differentiation. 2020 Jan 27
• 56 citations
  Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting
  Anne Slomp, Laura M Moesbergen, Jia-Nan Gong, Marta Cuenca, Peter A. von dem Borne, Pieter Sonneveld, David C.S. Huang, Monique C. Minnema, Victor Peperzak> ;Blood Advances. 2019 Dec 23
• 24 citations
  A small molecule interacts with VDAC2 to block mouse BAK-driven apoptosis.
  Mark F. van Delft, Stephane Chappaz, Yelena Khakham, Chinh T. Bui, Marlyse A. Debrincat, Kym N Lowes, Jason M. Brouwer, Christoph Grohmann, Phillip P. Sharp, Laura F. ...> ;Nature Chemical Biology. 2019 Oct 7
• 29 citations
  Replication stress induces mitotic death through parallel pathways regulated by WAPL and telomere deprotection
  V. Pragathi Masamsetti, Ronnie Ren Jie Low, Ka Sin Mak, Aisling O'Connor, Chris D. Riffikin, Noa Lamm, Laure Crabbe, Jan Karlseder, David C.S. Huang, Makoto T. Hayashi...> ;Nature Communications. 2019 Sep 17
• 31 citations
  Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma
  Piers Blombery, Richard W Birkinshaw, Tamia Nguyen, Jia-Nan Gong, Ella R. Thompson, Zhen Xu, David Westerman, Peter E. Czabotar, Michael Dickinson, David C.S. Huang, J...> ;British Journal of Haematology. 2019 Sep 1
• 10 citations
  Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes.
  Yuhao Jiao, Joanne E. Davis, Jai Rautela, Emma M. Carrington, Mandy J. Ludford-Menting, Wilford Goh, Rebecca B. Delconte, Fernando Souza-Fonseca-Guimaraes, Rachel Kold...> ;Cell Death and Differentiation. 2019 Aug 1
• 115 citations
  Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
  Richard W Birkinshaw, Jia-Nan Gong, Cindy S. Luo, Daisy Lio, Christine A White, Mary Ann Anderson, Piers Blombery, Guillaume Lessene, Ian J. Majewski, Rachel Thijssen,...> ;Nature Communications. 2019 Jun 3
• 115 citations
  Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
  Donia M Moujalled, Giovanna Pomilio, Corina Ghiurau, Adam Ivey, Jessica M. Salmon, Sewa Rijal, Sarah MacRaild, Lan Zhang, Tse-Chieh Teh, Ing Soo Tiong, Ping Lan, Maïa ...> ;Leukemia. 2019 Apr 1
• 246 citations
  Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
  Piers Blombery, Mary Ann Anderson, Jia-Nan Gong, Rachel Thijssen, Richard W Birkinshaw, Ella R. Thompson, Charis E Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, T...> ;Cancer Discovery. 2019 Mar 1
• 35 citations
  KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs.
  Huiqin Liu, Mengnan Sun, Zhengsheng Liu, Chao Kong, Weijian Kong, Junxiao Ye, Jia-Nan Gong, David C.S. Huang, Feng Qian> ;Journal of Controlled Release. 2019 Feb 28
• 124 citations
  Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.
  Rishu Agarwal, Yih-Chih Chan, Constantine S. Tam, Tane Hunter, Dane Vassiliadis, Charis E Teh, Rachel Thijssen, Paul Yeh, Stephen Q. Wong, Sarah Ftouni, Enid Y.N. Lam,...> ;Nature Medicine. 2019 Jan 1
• 247 citations
  AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.
  Sean Caenepeel, Sean P. Brown, Brian Belmontes, Gordon Moody, Kathleen S. Keegan, Danny Chui, Douglas A. Whittington, Xin Huang, Leszek Poppe, Alan C. Cheng, Mario G. ...> ;Cancer Discovery. 2018 Dec 1
• Join now to see all